tetano
Editor, Senior Moderator
J Neuroimmune Pharmacol
. 2021 Jan 6.
doi: 10.1007/s11481-020-09968-x. Online ahead of print.
Pharmacotherapeutics of SARS-CoV-2 Infections
Bhavesh D Kevadiya[SUP] 1 [/SUP], Jatin Machhi[SUP] 2 [/SUP], Jonathan Herskovitz[SUP] 2 3 [/SUP], Maxim D Oleynikov[SUP] 2 [/SUP], Wilson R Blomberg[SUP] 2 [/SUP], Neha Bajwa[SUP] 4 [/SUP], Dhruvkumar Soni[SUP] 5 [/SUP], Srijanee Das[SUP] 2 3 [/SUP], Mahmudul Hasan[SUP] 5 [/SUP], Milankumar Patel[SUP] 2 [/SUP], Ahmed M Senan[SUP] 6 [/SUP], Santhi Gorantla[SUP] 2 [/SUP], JoEllyn McMillan[SUP] 2 [/SUP], Benson Edagwa[SUP] 2 [/SUP], Robert Eisenberg[SUP] 7 [/SUP], Channabasavaiah B Gurumurthy[SUP] 2 [/SUP], St Patrick M Reid[SUP] 3 [/SUP], Chamindie Punyadeera[SUP] 8 [/SUP], Linda Chang[SUP] 9 [/SUP], Howard E Gendelman[SUP] 2 3 5 [/SUP]
Affiliations
Abstract
The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.
Keywords: Antibodies; Antivirals; COVID-19 therapeutics; SARS-CoV-2; Vaccine.
. 2021 Jan 6.
doi: 10.1007/s11481-020-09968-x. Online ahead of print.
Pharmacotherapeutics of SARS-CoV-2 Infections
Bhavesh D Kevadiya[SUP] 1 [/SUP], Jatin Machhi[SUP] 2 [/SUP], Jonathan Herskovitz[SUP] 2 3 [/SUP], Maxim D Oleynikov[SUP] 2 [/SUP], Wilson R Blomberg[SUP] 2 [/SUP], Neha Bajwa[SUP] 4 [/SUP], Dhruvkumar Soni[SUP] 5 [/SUP], Srijanee Das[SUP] 2 3 [/SUP], Mahmudul Hasan[SUP] 5 [/SUP], Milankumar Patel[SUP] 2 [/SUP], Ahmed M Senan[SUP] 6 [/SUP], Santhi Gorantla[SUP] 2 [/SUP], JoEllyn McMillan[SUP] 2 [/SUP], Benson Edagwa[SUP] 2 [/SUP], Robert Eisenberg[SUP] 7 [/SUP], Channabasavaiah B Gurumurthy[SUP] 2 [/SUP], St Patrick M Reid[SUP] 3 [/SUP], Chamindie Punyadeera[SUP] 8 [/SUP], Linda Chang[SUP] 9 [/SUP], Howard E Gendelman[SUP] 2 3 5 [/SUP]
Affiliations
- PMID: 33403500
- DOI: 10.1007/s11481-020-09968-x
Abstract
The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.
Keywords: Antibodies; Antivirals; COVID-19 therapeutics; SARS-CoV-2; Vaccine.